The efficacy of erythropoietin in treating experimental traumatic brain injury: A systematic review of controlled trials in animal models

Journal of Neurosurgery

Volumn 121, Issue 3, 2014, Pages 653-664

  Peng, Weijun ^a   Xing, Zhihua ^a   Yang, Jingjing ^a   Wang, Yang ^a   Wang, Weihao ^a   Huang, Wei ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Efficacy; Erythropoietin; Systematic review; Traumatic brain injury

Indexed keywords

NEUROPROTECTIVE AGENT; RECOMBINANT ERYTHROPOIETIN;

CLINICAL TRIAL (TOPIC); COGNITION; DRUG EFFICACY; HUMAN; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME;

EFFICACY; EPO = ERYTHROPOIETIN; ERYTHROPOIETIN; MNSS = MODIFIED NEUROLOGICAL SEVERITY SCORE; MWM = MORRIS WATER MAZE; SMD = STANDARDIZED MEAN DIFFERENCE; STAIR = STROKE THERAPY ACADEMIC INDUSTRY ROUNDTABLE; SYSTEMATIC REVIEW; TBI = TRAUMATIC BRAIN INJURY; TRAUMATIC BRAIN INJURY;

ANIMALS; BRAIN INJURIES; CONTROLLED CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; ERYTHROPOIETIN; FEMALE; MALE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; TREATMENT OUTCOME;

EID: 84907323322     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2014.6.JNS132577     Document Type: Review

References (53)

1. Akdemir Ozisik P, Oruckaptan H, Ozdemir Geyik P, Misirlioglu M, Sargon MF, Kilinc K, et al: Effect of erythropoietin on brain tissue after experimental head trauma in rats. Surg Neurol 68:547-555, 2007
2. Anderson GD, Peterson TC, Vonder Haar C, Kantor ED, Farin FM, Bammler TK, et al: Comparison of the effects of erythropoietin and anakinra on functional recovery and gene expression in a traumatic brain injury model. Front Pharmacol 4:129, 2013
3. Bouzat P, Francony G, Thomas S, Valable S, Mauconduit F, Fevre MC, et al: Reduced brain edema and functional deficits after treatment of diffuse traumatic brain injury by carbamylated erythropoietin derivative. Crit Care Med 39:2099-2105, 2011
4. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97:10526-10531, 2000
5. Cherian L, Goodman JC, Robertson C: Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats. J Pharmacol Exp Ther 322:789-794, 2007
6. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al: Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698-702, 1994
7. Cotena S, Piazza O, Tufano R: The use of erythtropoietin in cerebral diseases. Panminerva Med 50:185-192, 2008
8. Danos O, Davies K, Lehn P, Mulligan R: The ARRIVE guidelines, a welcome improvement to standards for reporting animal research. J Gene Med 12:559-560, 2010
9. Dirnagl U: Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab 26:1465-1478, 2006
10. Egger M, Smith GD, Schneider M, Minder C: Bias in metaanalysis detected by a simple, graphical test. BMJ 315:629-634, 1997
11. Feigin VL, Theadom A, Barker-Collo S, Starkey NJ, McPherson K, Kahan M, et al: Incidence of traumatic brain injury in New Zealand: a population-based study. Lancet Neurol 12:53-64, 2013
12. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al: Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40:2244-2250, 2009
13. Gibson CL, Gray LJ, Bath PM, Murphy SP: Progesterone for the treatment of experimental brain injury; a systematic review. Brain 131:318-328, 2008
14. Gibson CL, Gray LJ, Murphy SP, Bath PM: Estrogens and experimental ischemic stroke: a systematic review. J Cereb Blood Flow Metab 26:1103-1113, 2006
15. Grasso G, Sfacteria A, Meli F, Fodale V, Buemi M, Iacopino DG: Neuroprotection by erythropoietin administration after experimental traumatic brain injury. Brain Res 1182:99-105, 2007
16. Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0. Cochrane Collaboration, 2011 (http://handbook. cochrane.org/) [Accessed June 4, 2014]
17. Janowitz T, Menon DK: Exploring new routes for neuroprotective drug development in traumatic brain injury. Sci Transl Med 2:27rv1, 2010
18. Jerndal M, Forsberg K, Sena ES, Macleod MR, O'Collins VE, Linden T, et al: A systematic review and meta-analysis of erythropoietin in experimental stroke. J Cereb Blood Flow Metab 30:961-968, 2010
19. Ker K, Perel P, Blackhall K: Beta-2 receptor antagonists for traumatic brain injury: a systematic review of controlled trials in animal models. CNS Neurosci Ther 15:52-64, 2009
20. Kersel DA, Marsh NV, Havill JH, Sleigh JW: Psychosocial functioning during the year following severe traumatic brain injury. Brain Inj 15:683-696, 2001
21. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG: Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8:e1000412, 2010
22. Lu D, Mahmood A, Qu C, Goussev A, Schallert T, Chopp M: Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury. J Neurotrauma 22:1011-1017, 2005
23. Lu J, Frerich JM, Turtzo LC, Li S, Chiang J, Yang C, et al: Histone deacetylase inhibitors are neuroprotective and preserve NGF-mediated cell survival following traumatic brain injury. Proc Natl Acad Sci U S A 110:10747-10752, 2013
24. Macleod MR, O'Collins T, Horky LL, Howells DW, Donnan GA: Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab 25:713-721, 2005
25. Meng Y, Xiong Y, Mahmood A, Zhang Y, Qu C, Chopp M: Dose-dependent neurorestorative effects of delayed treatment of traumatic brain injury with recombinant human erythropoietin in rats. Laboratory investigation. J Neurosurg 115:550-560, 2011
26. Minnerup J, Heidrich J, Rogalewski A, Schäbitz WR, Wellmann J: The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis. Stroke 40:3113-3120, 2009
27. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354:1896-1900, 1999
28. Moja LP, Telaro E, D'Amico R, Moschetti I, Coe L, Liberati A: Assessment of methodological quality of primary studies by systematic reviews: results of the metaquality cross sectional study. BMJ 330:1053, 2005
29. Ning R, Xiong Y, Mahmood A, Zhang Y, Meng Y, Qu C, et al: Erythropoietin promotes neurovascular remodeling and long-term functional recovery in rats following traumatic brain injury. Brain Res 1384:140-150, 2011
30. Nirula R, Diaz-Arrastia R, Brasel K, Weigelt JA, Waxman K: Safety and efficacy of erythropoietin in traumatic brain injury patients: a pilot randomized trial. Crit Care Res Pract 2010:209848, 2010
31. Oxman AD, Guyatt GH: Guidelines for reading literature reviews. CMAJ 138:697-703, 1988
32. Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, et al: Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 334:197, 2007
33. Pound P, Ebrahim S, Sandercock P, Bracken MB, Roberts I: Where is the evidence that animal research benefits humans? BMJ 328:514-517, 2004
34. Prins M, Greco T, Alexander D, Giza CC: The pathophysiology of traumatic brain injury at a glance. Dis Model Mech 6:1307-1315, 2013
35. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC: Meta-analyses of randomized controlled trials. N Engl J Med 316:450-455, 1987
36. Sandercock P, Roberts I: Systematic reviews of animal experiments. Lancet 360:586, 2002
37. Stroke Therapy Academic Industry Roundtable (STAIR): Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30:2752-2758, 1999
38. Velly L, Pellegrini L, Guillet B, Bruder N, Pisano P: Erythropoietin 2nd cerebral protection after acute injuries: a double-edged sword? Pharmacol Ther 128:445-459, 2010
39. Wardlaw JM, Warlow CP, Sandercock PA, Dennis MS, Lindley RI: Neuroprotection disappointment yet aGAIN. Lancet 356:597, 2000 (Letter)
40. Washington PM, Forcelli PA, Wilkins T, Zapple DN, Parsadanian M, Burns MP: The effect of injury severity on behavior: a phenotypic study of cognitive and emotional deficits after mild, moderate, and severe controlled cortical impact injury in mice. J Neurotrauma 29:2283-2296, 2012
41. Willmot M, Gibson C, Gray L, Murphy S, Bath P: Nitric oxide synthase inhibitors in experimental ischemic stroke and their effects on infarct size and cerebral blood flow: a systematic review. Free Radic Biol Med 39:412-425, 2005
42. Willmot M, Gray L, Gibson C, Murphy S, Bath PM: A systematic review of nitric oxide donors and L-arginine in experimental stroke; effects on infarct size and cerebral blood flow. Nitric Oxide 12:141-149, 2005
43. Xiong Y, Lu D, Qu C, Goussev A, Schallert T, Mahmood A, et al: Effects of erythropoietin on reducing brain damage and improving functional outcome after traumatic brain injury in mice. Laboratory investigation. J Neurosurg 109:510-521, 2008
44. Xiong Y, Mahmood A, Chopp M: Animal models of traumatic brain injury. Nat Rev Neurosci 14:128-142, 2013
45. Xiong Y, Mahmood A, Lu D, Qu C, Goussev A, Schallert T, et al: Role of gender in outcome after traumatic brain injury and therapeutic effect of erythropoietin in mice. Brain Res 1185:301-312, 2007
46. Xiong Y, Mahmood A, Meng Y, Zhang Y, Qu C, Schallert T, et al: Delayed administration of erythropoietin reducing hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome following traumatic brain injury in rats: comparison of treatment with single and triple dose. Laboratory investigation. J Neurosurg 113:598-608, 2010
47. Xiong Y, Mahmood A, Qu C, Kazmi H, Zhang ZG, Noguchi CT, et al: Erythropoietin improves histological and functional outcomes after traumatic brain injury in mice in the absence of the neural erythropoietin receptor. J Neurotrauma 27:205-215, 2010
48. Xiong Y, Mahmood A, Zhang Y, Meng Y, Zhang ZG, Qu C, et al: Effects of posttraumatic carbamylated erythropoietin therapy on reducing lesion volume and hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome in rats following traumatic brain injury. Laboratory investigation. J Neurosurg 114:549-559, 2011
49. Xiong Y, Zhang Y, Mahmood A, Meng Y, Qu C, Chopp M: Erythropoietin mediates neurobehavioral recovery and neurovascular remodeling following traumatic brain injury in rats by increasing expression of vascular endothelial growth factor. Transl Stroke Res 2:619-632, 2011
50. Zhang Y, Chopp M, Mahmood A, Meng Y, Qu C, Xiong Y: Impact of inhibition of erythropoietin treatment-mediated neurogenesis in the dentate gyrus of the hippocampus on restoration of spatial learning after traumatic brain injury. Exp Neurol 235:336-344, 2012
51. Zhang Y, Xiong Y, Mahmood A, Meng Y, Liu Z, Qu C, et al: Sprouting of corticospinal tract axons from the contralateral hemisphere into the denervated side of the spinal cord is associated with functional recovery in adult rat after traumatic brain injury and erythropoietin treatment. Brain Res 1353:249-257, 2010
52. Zhang Y, Xiong Y, Mahmood A, Meng Y, Qu C, Schallert T, et al: Therapeutic effects of erythropoietin on histological and functional outcomes following traumatic brain injury in rats are independent of hematocrit. Brain Res 1294:153-164, 2009
53. Zhou JB, Yang JK: Angiotensin-converting enzyme gene polymorphism is associated with proliferative diabetic retinopathy: a meta-analysis. Acta Diabetol 47 (Suppl 1):187-193, 2010